article

DiabetesIstock

Funding for drug development to help tackle Type 1 Diabetes

Wednesday, 20 December 2023

Scientists have been awarded £3m to develop new targeted drugs to help people with Diabetes to make their own insulin that could pave the way for a cure for the disease.

Researchers from the University of Nottingham’s School of Pharmacy and University of Edinburgh have been awarded the funding as part of the Type 1 Diabetes Grand Challenge project to explore better and more innovative ways to improve the effectiveness of transplant islets, clusters of pancreas cells, into people with type 1 diabetes to enable them to make their own insulin.

The team are aiming to improve the benefits and availability of islet transplants by improving the drugs used as part of this treatment. The team will package microparticles with immune-altering and other drugs to improve the survival of transplanted islets. They will test different combinations of drugs in islet transplants in mice, to see which work best to help islets survive and control blood sugar levels.

The team will then run experiments to investigate how to scale up the dose of the drugs and how the treatment might work in humans and check if the most promising drug microparticle combinations also work to protect beta cells that have been grown in the lab from stem cells.

In an islet transplant, clusters cells (called islets) from a donor pancreas are transplanted into someone with type 1 diabetes and start to produce insulin. They’re currently offered to some people with type 1 diabetes who have severe hypos and no awareness of them. However, usually about 60% of the donor cells die soon after transplant.

This means lots of donor islets are needed to have an impact on blood sugar levels. But with a limited number of donor pancreases available for islet transplantation, very few people with type 1 diabetes can currently benefit.

Lisa-White-crop
Improving the survival of donor islets could pave the way for a cure for type 1 diabetes. We are hugely excited to be able to work on this collaborative project to develop microparticle systems that will allow us to deliver new targeted drugs to allow islet transplants to be successful for everyone who needs them.
Dr Lisa White, University of Nottingham, School of Pharmacy
I hope the Grand Challenge’s investment will give people living with type 1 diabetes hope that a cure can be achieved in their lifetime. The funding has allowed scientists from diverse fields to come together in this project with a common goal of doing some truly innovative research that will advance the field. By improving the benefits of human pancreas cell transplants, and in time transplants using stem cells, we hope to contribute towards a future where people with type 1 diabetes can live a life free from insulin injections.
Professor Shareen Forbes, University of Edinburgh

Story credits

More information is available Dr Lisa White on Lisa.White@nottingham.ac.uk

janeicke
Jane Icke - Media Relations Manager Science
Email: jane.icke@nottingham.ac.uk
Phone: 0115 7486462
Location:

Notes to editors:

About the University of Nottingham

Ranked 32 in Europe and 16th in the UK by the QS World University Rankings: Europe 2024, the University of Nottingham is a founding member of the Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.

Nottingham was crowned Sports University of the Year by The Times and Sunday Times Good University Guide 2024 – the third time it has been given the honour since 2018 – and by the Daily Mail University Guide 2024.

The university is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.

The university is a major employer and industry partner - locally and globally - and our graduates are the second most targeted by the UK's top employers, according to The Graduate Market in 2022 report by High Fliers Research.

We lead the Universities for Nottingham initiative, in partnership with Nottingham Trent University, a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.

More news…

Media Relations - External Relations

The University of Nottingham
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798
email: pressoffice@nottingham.ac.uk